Does Rallies show 13F holders for ARWR?

Yes. Rallies tracks hedge fund and 13F ownership data for ARWR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ARWR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARWR. It does not provide personalized investment advice.

ARWR (Arrowhead Research Corporation) Stock Analysis - Hedge Fund Holdings

Arrowhead Research Corporation (ARWR) is a publicly traded Healthcare sector company. As of May 20, 2026, ARWR trades at $76.75 with a market cap of $10.42B and a P/E ratio of -35.25. ARWR moved +5.35% today. Year to date, ARWR is +20.76%; over the trailing twelve months it is +373.54%. Its 52-week range spans $9.57 to $82.26. Analyst consensus is strong buy with an average price target of $89.25. Rallies surfaces ARWR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ARWR stock?

Hedge funds tracked by Rallies that own ARWR include Rokos Capital, Orbimed Advisors, Panagora Asset, Bridgewater Associates, and Centerbook Partners. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arrowhead Research Corporation.

ARWR Key Metrics

Key financial metrics for ARWR
Metric	Value
Price	$76.75
Market Cap	$10.42B
P/E Ratio	-35.25
EPS	$-2.17
Dividend Yield	0.00%
52-Week High	$82.26
52-Week Low	$9.57
Volume	1.25M
Avg Volume	0
Revenue (TTM)	$622.01M
Net Income	$-271.86M
Gross Margin	0.00%

Top Hedge Funds Holding ARWR

Rokos Capital holds 939.98K shares of ARWR, changed -61.76% as of Jun 30, 2024.
Orbimed Advisors holds 739.65K shares of ARWR, changed +131.39% as of Mar 31, 2024.
Panagora Asset holds 461.19K shares of ARWR, changed +1182.70% as of Mar 31, 2026.
Bridgewater Associates holds 95.55K shares of ARWR, changed +59.34% as of Mar 31, 2026.
Centerbook Partners holds 66.91K shares of ARWR, changed -80.91% as of Mar 31, 2025.

Latest ARWR News

Arrowhead Shares Jump 6.95% on Surge in AI-Driven Cardiac Diagnostics Market Forecast — May 12, 2026
Arrowhead Projects $73.8M Q2 Revenue, Gains ARO-PNPLA3 License and Australian Approval — May 7, 2026
Arrowhead climbs as traders buy ahead of May 7 earnings and EU Redemplo momentum — May 6, 2026
Arrowhead Grants Madrigal Global Rights to ARO-PNPLA3 with $25M Upfront, $975M Milestones — May 6, 2026
Arrowhead (ARWR) slides ahead of May 7 earnings webcast as caution builds — May 5, 2026

Recent ARWR Insider Trades

Lu Hongbo sold 2.97K (~$228.33K) on May 12, 2026.
Hamilton James C sold 10.00K (~$750.00K) on Apr 23, 2026.
Apel Daniel Joseph sold 3.21K (~$224.91K) on Apr 22, 2026.

ARWR Analyst Consensus

10 analysts cover ARWR: 0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.25.

Common questions about ARWR

Who owns ARWR stock?: Hedge funds tracked by Rallies that own ARWR include Rokos Capital, Orbimed Advisors, Panagora Asset, Bridgewater Associates, and Centerbook Partners. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Arrowhead Research Corporation.
Does Rallies show 13F holders for ARWR?: Yes. Rallies tracks hedge fund and 13F ownership data for ARWR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ARWR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARWR. It does not provide personalized investment advice.